Price · as of 2025
$16.08
Market cap 2.04B
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Aurinia Pharmaceuticals Inc. (AUPH) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Line items
Line items
Line items
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
- CEO
- Kevin C. Tang
- Employees
- 128
- Beta
- 1.42
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.